Clinical Trial Update: Guadecitabine Extension Study [Phase 2]

View source ↗

Summary

Phase 2 extension study of guadecitabine in acute myeloid leukemia and myelodysplastic syndrome was terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Guadecitabine (guadecitabine)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Acute Myeloid Leukemia, Myeloid Dysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2023-04-26